Recognition and treatment of neuropsychiatric disturbances in Parkinsons disease

Expert Review of Neurotherapeutics

Volumn 15, Issue 9, 2015, Pages 1053-1065

  Akbar, Umer ^a   Friedman, Joseph H ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

akathisia; anxiety; apathy; cognition; dementia; depression; fatigue; neuropsychiatric symptoms; non motor symptoms; Parkinson's disease; personality; sleep

Indexed keywords

NEUROLEPTIC AGENT;

AKATHISIA; ANXIETY DISORDER; APATHY; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; DEMENTIA; DEPRESSION; FATIGUE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HAMILTON DEPRESSION RATING SCALE; HUMAN; IMPULSE CONTROL DISORDER; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MONTREAL COGNITIVE ASSESSMENT; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PERSONALITY DISORDER; PSYCHOSIS; QUALITY OF LIFE; RECOGNITION; REVIEW; SLEEP DISORDER; BEHAVIOR; COMPLICATION; ETIOLOGY; THERAPY;

BEHAVIORAL SYMPTOMS; HUMANS; PARKINSON DISEASE; QUALITY OF LIFE;

EID: 84940718872     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1077703     Document Type: Review

References (109)

1. Chaudhuri KR, Sauerbier A, Rojo JM, et al. The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system. Parkinsonism Relat Disord 2015; 21(3):287-91
2. Zis P, Rizos A, Martinez-Martin P, et al. Non-motor symptoms profile and burden in drug naive versus long-term Parkinson's disease patients. J Parkinsons Dis 2014;4(3): 541-7
3. Wu Y, Guo XY, Wei QQ, et al. Determinants of the quality of life in Parkinson's disease: results of a cohort study from Southwest China. J Neurol Sci 2014; 340(1-2):144-9
4. Kim SR, So HY, Choi E, et al. Influencing effect of non-motor symptom clusters on quality of life in Parkinson's disease. J Neurol Sci 2014;347(1-2):310-15
5. Weintraub D, Burn DJ. Parkinson's disease: The quintessential neuropsychiatric disorder. Mov Disord 2011;26(6):1022-31
6. Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. Neurology 2007; 69(17):1701-11
7. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010;9(12):1200-13
8. Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol 2008;255(2):255-64
9. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010;289(1-2):18-22
10. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Mov Disord 2008;23(6):837-44
11. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22(12):1689-707
12. Mosimann UP, Mather G, Wesnes KA, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004;63(11):2091-6
13. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79(12):1331-8
14. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007;27(6):1405-10
15. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease: A community-based, prospective study. Neurology 2001;56(6):730-6
16. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005;20(10):1255-63
17. Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of [alpha]-synuclein, tau and amyloid-[beta] pathologies. Nature Reviews Neuroscience 2013;14(9):626-36
18. Anang JB, Gagnon JF, Bertrand JA, et al. Predictors of dementia in Parkinson disease A prospective cohort study. Neurology 2014;83(14):1253-60
19. Mak E, Su L, Williams GB, et al. Neuroimaging correlates of cognitive impairment and dementia in Parkinson's disease. Parkinsonism Relat Disord 2015; 21(8):862-70
20. Stav AL, Aarsland D, Johansen KK, et al. Amyloid-beta and alpha-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. Parkinsonism Relat Disord 2015;21(7):758-64
21. Lin CH, Wu RM. Biomarkers of cognitive decline in Parkinson's disease. Parkinsonism Relat Disord 2015;21(5):431-43
22. Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015;86(2):135-43
23. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study. Arch Neurol 2003;60(12):1745-8
24. Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54(2):407-11
25. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: A randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(10):969-77
26. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351(24):2509-18
27. Grace J, Amick MM, Friedman JH. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry 2009;80(1):18-23
28. Chou KL, Messing S, Oakes D, et al. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 2005;28(5):215-19
29. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007; 22(8):1061-8
30. Borek LL, Chou KL, JH, Friedman Management of the behavioral aspects of Parkinson's disease. Expert Rev Neurother 2007;7(6):711-25
31. Zahodne LB, Fernandez HH. Parkinson's psychosis. Curr Treat Options Neurol 2010; 12(3):200-11
32. Zhu K, van Hilten JJ, Putter H, Marinus J. Risk factors for hallucinations in Parkinson's disease: results from a large prospective cohort study. Mov Disord 2013;28(6): 755-62
33. Association, A. P., Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 2003: ManMag
34. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson study group. N Engl J Med 1999;340(10):757-63
35. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: A randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75(5): 689-95
36. Wolters EC, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990;40(5):832-4
37. Hack N, Fayad SM, Monari EH, et al. An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. PLoS One 2014;9(3):e91545
38. Fernandez HH, Roberts VJ, Evatt ML, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinicalpolysomnography study. Int J Neurosci 2009;119(12):2196-205
39. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20(8):958-63
40. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: A double-blind labeled study of 3 months' duration. Mov Disord 2007;22(3):313-18
41. Shotbolt P, Samuel M, Fox C, et al. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat 2009;5:327-32
42. Friedman JH. Melperone is ineffective in treating Parkinson's disease psychosis. Mov Disord 2012;27(6):803-4
43. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: A randomised, placebo-controlled phase 3 trial. Lancet 2014;383(9916):533-40
44. Friedman JH. Pimavanserin for the treatment of Parkinson's disease psychosis. Expert Opin Pharmacother 2013;14(14): 1969-75
45. Friedman JH, Brown RG, Comella C, et al. Fatigue in Parkinson's disease: A review. Mov Disord 2007;22(3):297-308
46. Brown RG, Dittner A, Findley L, et al. The Parkinson fatigue scale. Parkinsonism Relat Disord 2005;11(1):49-55
47. Cochrane GD, Rizvi S, Abrantes AM, et al. The association between fatigue and apathy in patients with either Parkinson's disease or multiple sclerosis. Parkinsonism Relat Disord 2015. [Epub ahead of print]
48. Friedman JH, Friedman H. Fatigue in Parkinson's disease: A nine-year follow-up. Mov Disord 2001;16(6):1120-2
49. Garber CE, Friedman JH. Effects of fatigue on physical activity and function in patients with Parkinson's disease. Neurology 2003; 60(7):1119-24
50. Schifitto G, Friedman JH, Oakes D, et al. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology 2008;71(7): 481-5
51. Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology 2004;63(10):1908-11
52. Mendonca DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial. Mov Disord 2007;22(14):2070-6
53. Sheng P, Hou L, Wang X, et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: A systematic review and meta-analysis. PLoS One 2013;8(12): e81802
54. Lavretsky H, Reinlieb M, St Cyr N, et al. Citalopram, Methylphenidate, or their combination in geriatric depression: A randomized, Double-blind, Placebo-controlled Trial. Am J Psychiatry 2015;172(6):561-9
55. Marsh L, McDonald WM, Cummings J, et al. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006;21(2):148-58
56. Marsh L. Depression and Parkinson's disease: current knowledge. Curr Neurol Neurosci Rep 2013;13(12):409
57. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: A quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986;49(4): 381-9
58. Torbey E, Pachana NA, Dissanayaka NN. Depression rating scales in Parkinson's disease: A critical review updating recent literature. J Affect Disord 2015;184:216-24
59. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson's disease: A review and meta-analysis. Mov Disord 2005;20(9):1161-9
60. Pae CU. Use of antidepressants for depression in patients with Parkinson's disease. Expert Opin Pharmacother 2013; 14(3):255
61. Bomasang-Layno E, Fadlon I, Murray AN, et al. Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord 2015;21(8):833-42
62. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: A randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(6):573-80
63. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72(10):886-92
64. Menza M, Dobkin RD, Marin H, et al. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Mov Disord 2009;24(9):1325-32
65. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012;78(16): 1229-36
66. Friedman JH, Weintraub D. Glad about SAD (PD). Neurology 2012;78(16):1198-9
67. Skapinakis P, Bakola E, Salanti G, et al. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: A systematic review and meta-analysis of randomized controlled trials. BMC Neurol 2010;10:49
68. Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26(Suppl 3):S42-80
69. Dobkin R. D, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson's disease: A randomized, controlled trial. Am J Psychiatry 2011; 168(10):1066-74
70. Dobkin R. D, Menza M, Allen LA, et al. Telephone-based cognitive-behavioral therapy for depression in Parkinson disease. J Geriatr Psychiatry Neurol 2011;24(4): 206-14
71. Sproesser E, Viana MA, Quagliato EM, et al. The effect of psychotherapy in patients with PD: A controlled study. Parkinsonism Relat Disord 2010;16(4): 298-300
72. Armento ME, Stanley MA, Marsh L, et al. Cognitive behavioral therapy for depression and anxiety in Parkinson's disease: A clinical review. J Parkinsons Dis 2012;2(2):135-51
73. Fernie BA, Kollmann J, Brown RG. Cognitive behavioural interventions for depression in chronic neurological conditions: A systematic review. J Psychosom Res 2015;78(5):411-19
74. Faber R, Trimble MR. Electroconvulsive therapy in Parkinson's disease and other movement disorders. Mov Disord 1991; 6(4):293-303
75. Usui C, Hatta K, Doi N, et al. Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(7):1704-8
76. Ducharme S, Flaherty AW, Seiner SJ, et al. Temporary interruption of deep brain stimulation for Parkinson's disease during outpatient electroconvulsive therapy for major depression: A novel treatment strategy. J Neuropsychiatry Clin Neurosci 2011; 23(2):194-7
77. Vonloh M, Chen R, Kluger B. Safety of transcranial magnetic stimulation in Parkinson's disease: A review of the literature. Parkinsonism Relat Disord 2013; 19(6):573-85
78. Pagonabarraga J, Kulisevsky J, Strafella AP, et al. Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurology 2015;14(5): 518-31
79. Devos D, Moreau C, Maltête D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: A double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry 2014;85(6):668-74
80. Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002; 14(4):461-2
81. Djamshidian A, Friedman JH. Anxiety and depression in Parkinson's disease. Curr Treat Options Neurol 2014;16(4):285
82. Henderson R, Kurlan R, Kersun JM, et al. Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992;4(3):257-64
83. Leentjens AF, Dujardin K, Marsh L, et al. Anxiety and motor fluctuations in Parkinson's disease: A cross-sectional observational study. Parkinsonism Relat Disord 2012;18(10):1084-8
84. Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med 2005;46(2):227-32
85. Lindqvist D, Hall S, Surova Y, et al. Cerebrospinal fluid inflammatory markers in Parkinson's disease-associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 2013;33: 183-9
86. Troeung L, Egan SJ, Gasson N. A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson's disease. BMC Psychiatry 2014;14:19
87. Smith KM, Eyal E, Weintraub D, et al. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol 2015;72(1):88-95
88. Marino L, Friedman JH. Letter to the editor: successful use of electroconvulsive therapy for refractory anxiety in Parkinson's disease. Int J Neurosci 2013;123(1):70-1
89. Schapira AH. Excessive daytime sleepiness in Parkinson's disease. Neurology 2004; 63(8 Suppl 3):S24-7
90. Ylikoski A, Martikainen K, Partinen M. Parasomnias and isolated sleep symptoms in Parkinson's disease: A questionnaire study on 661 patients. J Neurol Sci 2014;346(1-2): 204-8
91. Di Fabio N, Poryazova R, Oberholzer M, et al. Sleepwalking, REM sleep behaviour disorder and overlap parasomnia in patients with Parkinson's disease. Eur Neurol 2013; 70(5-6):297-303
92. Verbaan D, van Rooden SM, van Hilten JJ, et al. Prevalence and clinical profile of restless legs syndrome in Parkinson's disease. Mov Disord 2010;25(13):2142-7
93. Zeng J, Wei M, Li T, et al. Risk of obstructive sleep apnea in Parkinson's disease: A meta-analysis. PLoS One 2013; 8(12):e82091
94. Diederich NJ, McIntyre DJ. Sleep disorders in Parkinson's disease: many causes, few therapeutic options. J Neurol Sci 2012; 314(1-2):12-19
95. Trotti LM, Bliwise DL. Treatment of the sleep disorders associated with Parkinson's disease. Neurotherapeutics 2014;11(1):68-77
96. Friedman JH, Agarwal P, Alcalay R, et al. Clinical vignettes in Parkinson's disease: A collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. Int J Neurosci 2011;121(8): 472-6
97. Lyons KE, Friedman JH, Hermanowicz N, et al. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol 2010;33(1):5-10
98. Drake RE, Ehrlich J. Suicide attempts associated with akathisia. Am J Psychiatry 1985;142(4):499-501
99. Lang AE, Johnson K. Akathisia in idiopathic Parkinson's disease. Neurology 1987;37(3):477-81
100. Cochrane GD, et al. Internal Tremor in Parkinson's Disease, Multiple Sclerosis, and Essential Tremor. Parkinsonism Relat Disord 2015
101. Linazasoro G, Marti Masso JF, Suarez JA. Nocturnal akathisia in Parkinson's disease: Treatment with clozapine. Mov Disord 1993;8(2):171-4
102. Camp CD. Paralysis agitans and multiple sclerosis and their treatment 1913
103. Booth G. Psychodynamics in parkinsonism. Psychosom Med 1948;10(1):1-14
104. Prick J. Genuine parkinsonism. A psychosomatic, anthropological-psychiatric approach. in Abs World Congress of Psychiatry Madrid 1966
105. Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson's disease: A randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72(6):708-12
106. Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study. Mov Disord 2012; 27(10):1230-8
107. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19(1):1-8
108. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: A double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8(7): 613-18
109. Leroi I, Overshott R, Byrne EJ, et al. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 2009;24(8):1217-21